Sense Announces Increase Of Series B To $65 Million To Support Launch Of Rapid, Point-Of-Care Molecular Diagnostic
Sense Announces Increase Of Series B To $65 Million To Support Launch Of Rapid, Point-Of-Care Molecular Diagnostic
11/17/21, 1:00 PM
Location
bostonRound Type
series b
Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced that after achieving several key milestones this year, the company’s Series B funding round has been increased to $65M, an additional $15 million from prior commitments. The round was led by existing investor Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, Inc.
Company Info
Location
boston, massachusetts, united states
Additional Info
Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros™ product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health, Sense is growing rapidly as it prepares to launch Veros™ COVID-19 and build a portfolio of additional tests for other diseases.
For more information, visit https://sense-bio.com/ and follow the company on Twitter at @sensedx1 and on LinkedIn at @Sense Biodetection Ltd.